KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBIT Margin (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed EBIT Margin for 18 consecutive years, with 17.83% as the latest value for Q1 2026.

  • For Q1 2026, EBIT Margin fell 170.0% year-over-year to 17.83%; the TTM value through Mar 2026 reached 24.32%, down 287.0%, while the annual FY2025 figure was 24.95%, 315.0% down from the prior year.
  • EBIT Margin hit 17.83% in Q1 2026 for Regeneron Pharmaceuticals, down from 22.65% in the prior quarter.
  • Across five years, EBIT Margin topped out at 2517.0% in Q1 2022 and bottomed at 17.83% in Q1 2026.
  • Average EBIT Margin over 5 years is 240.97%, with a median of 29.94% recorded in 2023.
  • Year-over-year, EBIT Margin surged 247300bps in 2022 and then tumbled -248706bps in 2023.
  • Regeneron Pharmaceuticals' EBIT Margin stood at 1146.8% in 2022, then tumbled by -98bps to 28.33% in 2023, then dropped by -8bps to 26.13% in 2024, then fell by -13bps to 22.65% in 2025, then fell by -21bps to 17.83% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 17.83%, 22.65%, and 27.35% for Q1 2026, Q4 2025, and Q3 2025 respectively.